신주발행 공고 (2026.09.14)
본사는 2026년 09월 14일 이사회에서 전환우선주식 제4종 1,035주의 신주발행을 결의하였으므로 상법 제418조에 따라 이를 공고합니다.
Read more →Latest News
Stay updated with our latest developments, research breakthroughs, and company announcements
Bionsight Selected for Samsung Bioepis Open Innovation Program
Bionsight has been selected for the 2026 Seoul Bio Hub–Samsung Bioepis Open Innovation Program, recognized for its AI- and DIA-MS-based proteome-wide target discovery platform.
Read more →
Bionsight @ BIO International Convention 2026
Bionsight's CSO Namgil Lee attended the BIO International Convention 2026 in San Diego, promoting the company and pursuing partnering opportunities with global pharmaceutical companies.
Read more →
Bionsight @ ASMS 2026
Bionsight presented two posters at ASMS 2026, sharing its latest mass spectrometry–based research with the global proteomics community.
Read more →
Bionsight Selected to Pitch at BioTools Innovator 2026
Bionsight has been selected to pitch at the BioTools Innovator 2026 Road Tour, joining roughly 15% of global applicants invited to present to investors and industry leaders.
Read more →Welcome to Bionsight
We are excited to launch our new website and share our vision for revolutionizing drug discovery through AI and chemoproteomics.
Read more →Bionsight & Scale-up TIPS
Selected for the “Scale-up TIPS” program by the Ministry of SMEs and Startups
Read more →Bionsight Series A Funding
Successfully raises Series A funding for drug discovery innovation
Read more →Bionsight @ Merck Research Grants
Bionsight selected as the finalist team in 2022 Merck Research Grants.
Read more →